Women with extremely dense breasts and a high breast cancer risk have a lower risk for advanced cancer when screened by digital breast tomosynthesis than digital mammography, US study findings indicate.
Circulating tumor DNA monitoring for minimal residual disease can identify patients at risk for distant relapse more than 5 years after diagnosis of high-risk, stage II–III hormone receptor-positive breast cancer, research shows.
Radiotherapy may not be necessary for patients with the luminal A breast cancer intrinsic subtype and a low clinical risk for recurrence, report the LUMINA investigators.
Adding capivasertib to fulvestrant significantly improves survival in patients with aromatase inhibitor resistant, estrogen receptor-positive, HER2-negative advanced breast cancer, particularly those with PIK3CA/AKT1/PTEN alterations, FAKTION data show.
Trastuzumab deruxtecan significantly improves the survival outcomes of previously treated patients with HER2-low metastatic breast cancer relative to standard chemotherapy, show DESTINY-Breast04 data.
Patients with metastatic breast cancer who progress during combination treatment with a CDK4/6 inhibitor and endocrine therapy may benefit from switching endocrine therapy and combining it with ribociclib, MAINTAIN study findings indicate.